文献速递白血病淋巴瘤

芦可替尼治疗复发/难治性大颗粒淋巴细胞白血病的疗效

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2024-04-19

该研究报告21例复发/难治性大颗粒淋巴细胞白血病患者接受芦可替尼治疗的结果:总缓解率86%(18/21),含3例完全缓解和15例部分缓解;中位随访9个月时中位缓解持续时间4个月,1年无事件生存率57%、1年总生存率83%,观察到轻度副作用,中性粒细胞减少和贫血等生物学参数显著改善。

要点

  • 芦可替尼治疗复发/难治性LGL白血病总缓解率86%(18/21),含3例完全缓解、15例部分缓解。
  • 中位随访9个月,中位缓解持续时间4个月,1年无事件生存率57%、1年总生存率83%。
  • 观察到轻度副作用,中性粒细胞减少和贫血等生物学参数显著改善。

核心结论

  • 本研究支持芦可替尼作为复发/难治性LGL白血病治疗的有效选择。

研究设计与样本

  • 报告21例接受芦可替尼治疗的复发/难治性LGL白血病患者系列。
  • 10例(47.6%)在开始芦可替尼时对三种主要免疫抑制药物难治。

主要发现

  • 芦可替尼总缓解率86%(n=18/21),包括3例完全缓解和15例部分缓解。
  • 中位随访9个月,中位缓解持续时间4个月。
  • 1年无事件生存率57%,1年总生存率83%。
  • 观察到轻度副作用。
  • 生物学参数(尤其是中性粒细胞减少和贫血)显著改善,并证实完全分子学缓解。

临床怎么用

  • 作者认为芦可替尼是复发/难治性LGL白血病治疗的有效选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells. Despite a usually indolent evolution, most patients will require a treatment over the course of the disease because of cytopenia or symptomatic associated autoimmune disorders. First-line treatment is based on immunosuppressive agents, namely cyclophosphamide, methotrexate and ciclosporin. However, relapses are frequent, and there is no consensus on the management of relapsed/refractory patients. The implication of the JAK/STAT pathway in the pathogenesis of this disease has prompted our group to propose treatment with ruxolitinib. A series of 21 patients who received this regimen is reported here. Ten patients (47.6%) were refractory to the three main immunosuppressive drugs at the time of ruxolitinib initiation. Ruxolitinib yielded an overall response rate of 86% (n = 18/21), including 3 complete responses and 15 partial responses. With a median follow-up of 9 months, the median response duration was 4 months. One-year event-free survival and 1-year overall survival were 57% and 83% respectively. Mild side effects were observed. Biological parameters, notably neutropenia and anaemia, improved significantly, and complete molecular responses were evidenced. This study supports ruxolitinib as a valid option for the treatment of relapsed/refractory LGL leukaemia.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Marchand T, Pastoret C, Damaj G, et al. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. Br J Haematol. 2024. PMID: 38639192. doi:10.1111/bjh.19476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。